The discovery of the chromosomal rearrangement leading to TMPRSS2-ERG fusion oncogene, present in more than 50% cases of prostate cancers, has opened important diagnostic and therapeutic perspectives for the treatment of one of the most frequent epithelial tumours in men. Here, ERG is linked to prostate carcinoma.